EA201991591A1 - NEUTRALIZING ANTI-HIV-1 ANTIBODIES OF A WIDE SPECTRUM OF ACTION AND WAYS OF THEIR APPLICATION - Google Patents

NEUTRALIZING ANTI-HIV-1 ANTIBODIES OF A WIDE SPECTRUM OF ACTION AND WAYS OF THEIR APPLICATION

Info

Publication number
EA201991591A1
EA201991591A1 EA201991591A EA201991591A EA201991591A1 EA 201991591 A1 EA201991591 A1 EA 201991591A1 EA 201991591 A EA201991591 A EA 201991591A EA 201991591 A EA201991591 A EA 201991591A EA 201991591 A1 EA201991591 A1 EA 201991591A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hiv
antibodies
ways
action
wide spectrum
Prior art date
Application number
EA201991591A
Other languages
Russian (ru)
Inventor
Мишель Нуссенцвейг
Наталия Т. Фройнд
Памела Дж. Бьеркман
Луиз Шарф
Original Assignee
Дзе Рокфеллер Юниверсити
Кэлифорниа Инститьют Оф Текнолоджи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Рокфеллер Юниверсити, Кэлифорниа Инститьют Оф Текнолоджи filed Critical Дзе Рокфеллер Юниверсити
Priority claimed from PCT/US2017/068235 external-priority patent/WO2018125813A1/en
Publication of EA201991591A1 publication Critical patent/EA201991591A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к нейтрализующим и эффективным анти-ВИЧ-1 антителам широкого спектра действия, наборам и способам их применения.The present invention relates to neutralizing and effective anti-HIV-1 antibodies with a wide spectrum of activity, kits and methods for their use.

EA201991591A 2017-01-11 2017-12-22 NEUTRALIZING ANTI-HIV-1 ANTIBODIES OF A WIDE SPECTRUM OF ACTION AND WAYS OF THEIR APPLICATION EA201991591A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762444946P 2017-01-11 2017-01-11
PCT/US2017/068235 WO2018125813A1 (en) 2016-12-27 2017-12-22 Broadly neutralizing anti-hiv-1 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
EA201991591A1 true EA201991591A1 (en) 2020-03-20

Family

ID=69942815

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991591A EA201991591A1 (en) 2017-01-11 2017-12-22 NEUTRALIZING ANTI-HIV-1 ANTIBODIES OF A WIDE SPECTRUM OF ACTION AND WAYS OF THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA201991591A1 (en)

Similar Documents

Publication Publication Date Title
EA202092435A3 (en) MONOCLONAL ANTIBODIES AGAINST BCMA
CO2018003500A2 (en) Anti-pd-1 antibodies and compositions
EA201990912A1 (en) ANTI-LAG-3 ANTIBODIES AND THEIR COMPOSITIONS
EA201890712A1 (en) ANTIBODIES TO PROTECTION / LATENT MIOSTATIN AND THEIR APPLICATION
EA201791029A1 (en) ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION
EA201791773A1 (en) CYTESTINE PROTEASIS
EA201892581A1 (en) COMBINED THERAPY OPTIONS BY HDAC INHIBITORS AND PD-L1 INHIBITORS
EA201890285A1 (en) ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
EA201891201A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890050A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890049A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
WO2016149710A3 (en) Hiv-1 neutralizing antibodies and uses thereof
EA201991214A1 (en) ANTIBODIES AGAINST PD-1 AND THEIR COMPOSITION
EA201790984A1 (en) ANTI-CD79B ANTIBODIES AND METHODS OF THEIR APPLICATION
EA201691610A8 (en) ANTI-JAGGED1 ANTIBODIES AND METHODS OF APPLICATION
EA201691488A1 (en) ANTIBODY MOLECULES AGAINST PD-1 AND THEIR APPLICATIONS
EA201891539A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201890093A1 (en) COMBINED THERAPY OF HEMOBLASTOSIS BY ANTIBODIES TO CD38 AND INHIBITORS Survivin
EA201591974A1 (en) HUMAN ANTIBODIES CONNECTING WITH RSV G-PROTEIN
EA201792220A1 (en) ANTIBODY-MEDIATED NEUTRALIZATION OF THE CHICUNG VIRUS VIRUS
MX2019007738A (en) Broadly neutralizing anti-hiv-1 antibodies and methods of use thereof.
EA202091731A1 (en) AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS
MX2020010951A (en) Anti-hla-g antibodies and use thereof.
EA201691541A1 (en) NEW ANTI-BAFF ANTIBODIES
CL2019001381A1 (en) Method for the treatment of focal segmental glomerulosclerosis.